In:
Hormone and Metabolic Research, Georg Thieme Verlag KG, Vol. 54, No. 01 ( 2022-01), p. 25-32
Abstract:
The short-term effects of long-acting somatostatin analogues (SSAs) on lipid
profiles in patients with acromegaly are not well studied. We retrospectively analyzed the effects of SSAs on lipid profiles and associated cardiovascular
risk factors in a cohort of 120 newly diagnosed acromegaly patients. In this study, 69 females and 51 males were included. These patients were treated with
either octreotide LAR (OCT) or lanreotide SR (LAN) for 3 months. After SSAs treatment, both GH and IGF-1 significantly decreased (p 〈 0.001).
Triglyceride (TG), total to high-density lipoprotein cholesterol (HDL-C) ratio, and lipoprotein (a) [Lp(a)] levels were significantly decreased, while HDL-C levels were increased (p 〈 0.05). The reduction of mean serum GH
(GHm) was positively associated with the decrease of TG (r=0.305, p=0.001) and Lp(a) (r=0.257, p=0.005),
as well as the increase of HDL-C (r=−0.355, p 〈 0.001).
The changes of lipid profiles were observed only in OCT group, but not in LAN group. In addition, systolic blood pressure (SBP) had significantly declined
after SSAs treatment, with an average reduction of 4.4 mmHg (126.7±1.28 vs. 122.3±1.44 mmHg, p=0.003), while
no change was observed regarding diastolic blood pressure (DBP) (p 〉 0.05). Fasting insulin, fasting C-peptide, and HOMA-IR were
significantly decreased after SSAs treatment. In conclusion, our current study revealed that short-term SSAs treatment improves lipid profiles and other
cardiovascular risk factors in patients with acromegaly.
Type of Medium:
Online Resource
ISSN:
0018-5043
,
1439-4286
Language:
English
Publisher:
Georg Thieme Verlag KG
Publication Date:
2022
detail.hit.zdb_id:
2056576-8
Permalink